DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category ARDX
Ardelyx Inc
Ardelyx Inc. (Nasdaq: $ARDX): The Growth Story Is No Longer Theoretical
Ardelyx is now a commercial-stage biotech where the core debate has moved from “can the product sell?” to “can the company turn rapid product growth into durable operating leverage?” That shift matters. It means $ARDX is no longer trading purely as a binary FDA story or early-launch hope. It is trading as a real revenue company with two approved U.S. products, a differentiated NHE3 biology platform, a growth engine in IBSRELA, a more complicated but still relevant kidney franchise in XPHOZAH, and a pipeline extension strategy that could make today’s commercial infrastructure more valuable over time.
Ardelyx Inc (ARDX) Growth is real, panic is optional: what Q4 2025 earnings really say
The market reaction to Ardelyx’s Q4 2025 earnings was simple and brutal: the stock lost roughly fifteen percent in the days after the print, sending a message that “something is wrong”. If you stop at the chart, it looks like a broken story. If you read the filings, the picture is very different: this is a company that is clearly growing, but still paying a high price in operating expenses to sustain that growth.
Biotech Catalyst Calendar February 2026: PDUFA, BLA & Clinical Results
Biotech Catalyst Calendar February 2026: PDUFA, BLA & Clinical Results
One-page view of the key February 2026 biotech catalysts: only one line per ticker, grouped by date. Fixed PDUFA and BLA events are listed first; the others are February-window guidance from company and Street sources.
ARDX Ardelyx Inc Updated Jan 8
Q3 2025: revenue beat, IBSRELA guidance raised, Street now models ARDX turning profitable in 2026
October–December 2025 – Q3 revenue beat, IBSRELA guidance increased to $270–275M for 2025, XPHOZAH absorbs Medicare shock, analysts talk about 2026 breakeven.